Switching from Lithium Immediate-Release to Controlled-Release
When switching from lithium IR to lithium CR, use a 1:1 dose conversion and maintain the same total daily dose, checking serum lithium levels 4-5 days after the switch to ensure therapeutic levels remain between 0.6-1.2 mEq/L.
Dose Conversion Strategy
The conversion is straightforward: use the exact same total daily milligram dose when switching formulations 1. For example, if a patient takes lithium carbonate 300 mg three times daily (900 mg total), switch to lithium CR 450 mg twice daily (same 900 mg total).
Key Pharmacokinetic Differences to Understand
The CR formulation has distinct absorption characteristics that affect monitoring:
- Peak concentration timing: IR peaks at 1-2 hours, while CR peaks at 4-5 hours 2
- Peak level reduction: CR formulations produce 30-50% lower peak concentrations without changing total drug exposure 2
- Steady-state achievement: Both formulations reach steady state in approximately 5 days (4-5 half-lives)
Monitoring Protocol
Timing of Serum Lithium Levels
Check the first post-switch lithium level 4-5 days after conversion (when steady state is reached). Draw blood samples 12 hours after the last dose for standardized monitoring 1. If using once-daily CR dosing, the 24-hour trough serves as the control value 2.
Target Therapeutic Range
Maintain serum concentrations between 0.6-0.8 mEq/L for most patients 3. The evidence supports this lower range compared to older recommendations of 0.8-1.2 mEq/L, as it provides adequate efficacy with better tolerability, particularly when lithium is combined with other medications 3.
For CR formulations specifically, some experts recommend targeting the upper end of this range (0.7-0.8 mEq/L) because the later peak concentration means the 12-hour level may underestimate average exposure 2.
Ongoing Monitoring Schedule
- Acute phase: Check lithium levels twice weekly until stable 1
- Maintenance phase: Monitor every 2 months minimum 1
- Renal and thyroid function: Every 3-6 months 4
- Additional monitoring: Check more frequently if dose changes or patient becomes acutely unwell 5
Clinical Advantages of CR Formulation
The switch to CR offers several benefits supported by recent evidence:
Reduced side effects: CR formulations significantly decrease tremor (62.9% improvement vs 20% with IR at 1 week, p=0.0006) 6. They also reduce gastrointestinal side effects 7.
Better adherence: The twice-daily or once-daily dosing schedule improves treatment adherence compared to three-times-daily IR dosing 6, 8, 7.
More stable blood levels: CR formulations produce less peak-to-trough variation, potentially reducing toxicity risk while maintaining efficacy 9, 7.
Critical Safety Considerations
Contraindications and Cautions
Do not switch formulations (or use lithium at all) in patients with 1:
- Significant renal impairment (GFR <30 mL/min/1.73 m²)
- Severe cardiovascular disease
- Severe dehydration or sodium depletion
- Concurrent diuretic use (relative contraindication)
Drug Interactions to Avoid
NSAIDs are contraindicated with lithium as they reduce renal clearance and increase toxicity risk 5. ACE inhibitors and ARBs also increase lithium levels and require close monitoring 5.
Age-Related Adjustments
Elderly patients (>60 years) should target the lower end of the therapeutic range (0.5-0.6 mEq/L) as they are more prone to neurotoxicity and typically require lower doses (15-20 mmol or 550-740 mg daily) 2, 3.
Common Pitfall to Avoid
Do not assume dose equivalence means identical serum levels immediately after switching. While the total daily dose remains the same, individual absorption patterns may vary. Some patients may need minor dose adjustments (typically ±150-300 mg daily) after checking the first steady-state level to achieve optimal therapeutic concentrations.
The CR formulation's later peak means that if you draw levels too early (before 4-5 days), you may incorrectly conclude the dose is inadequate and inappropriately increase it, risking toxicity once steady state is truly reached.